TABLE II.

Metastatic sites: frequency at initial diagnosis and three-year cumulative incidence rate^a by EGFR mutation status

Site	Frequency							Cumulative incidence (%)
	Overall		EGFR WT		EGFR-positive		p Valueb	Overall		EGFRWT		EGFR-positive		p Valuec
	(n)	(%)	(n)	(%)	(n)	(%)		Rate	95% CI	Rate	95% CI	Rate	95% CI
Lung	287	52.9	215	50.9	72	59.5	0.10	53.2	48.9 to 57.3	51.0	46.1 to 55.6	61.2	51.8 to 69.2	0.048
Bone	211	38.9	167	39.6	44	36.4	0.60	40.4	36.2 to 44.5	40.8	36.1 to 45.4	38.9	30.2 to 47.6	0.65
Brain	118	21.7	89	21.1	29	24.0	0.53	30.7	26.8 to 34.6	28.2	23.9 to 32.6	39.2	30.4 to 47.9	0.038
Liver	62	11.4	48	11.4	14	11.6	1.00	12.4	9.8 to 15.3	12.1	9.2 to 15.4	13.2	7.9 to 20	0.74
Adrenal gland	59	10.9	49	11.6	10	8.3	0.41	11.1	8.6 to 13.9	11.9	9 to 15.1	8.3	4.2 to 14	0.27
Distal nodes	56	10.3	44	10.4	12	9.9	1.00	10.7	8.3 to 13.5	10.9	8.2 to 14.2	9.9	5.4 to 16	0.75
Soft tissue	22	4.1	17	4.0	5	4.1	1.00	4.8	3.2 to 6.8	4.8	3 to 7.1	5.0	2 to 9.9	0.93
Pericardium	15	2.8	10	2.4	5	4.1	0.34	3.1	1.9 to 4.9	2.6	1.4 to 4.5	5.0	2 to 9.9	0.19
Spleen	6	1.1	4	0.9	2	1.7	0.62	1.1	0.5 to 2.3	0.9	0.3 to 2.3	1.7	0.3 to 5.3	0.51
Kidney	2	0.4	1	0.2	1	0.8	0.40	0.4	0.1 to 1.3	0.2	0 to 1.3	0.8	0.1 to 4.1	0.35

^aEstimated using a competing-risks method.

^bCalculated using the Fisher exact test.

^cCalculated using the Gray test.

WT = wild type; CI = confidence interval.